Navigation Links
IDM Pharma Announces Upcoming Clinical Data Presentations
Date:10/26/2007

IRVINE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI), a biotechnology company focused on the development of innovative cancer therapies, today announced details on clinical data presentations evaluating three of the Company's pipeline compounds to be presented at upcoming medical congresses.

Specific presentation details are as follows:

Mifamurtide (L-MTP-PE):

Connective Tissue Oncology Society (CTOS) -- Seattle, Wash.

Oral presentation -- Thursday, November 1, 1:30 p.m. PDT

"Osteosarcoma: Improved Outcome of Muramyl Tripeptide (MTP) to Cisplatin, Doxorubicin, High Dose Methotrexate +/- Ifosfamide."

Dr. Paul Meyers, principal investigator, vice chairman, department of pediatrics at Memorial Sloan Kettering Cancer Center

Abstract #780

The 39th Congress of International Society of Pediatric Oncology (SIOP) -- Mumbai, India

Poster presentation -- Friday, November 2, 4:30 -- 6 a.m. EDT

"Lung and Bone Specific Site-Directed Therapy of Osteosarcoma"

Dr. Johannes Wolff, professor of pediatrics, The University of Texas M.D. Anderson Cancer Center in Houston

Dr. Maurizio Ghisoli, fellow, pediatric oncology and hematology, The University of Texas M.D. Anderson Cancer Center in Houston

Poster #PD.037

IDM-2101:

International Society for Biological Therapy of Cancer (iSBTc) -- Boston, Mass.

Oral presentation (Vaccines/Dendritic Cells) -- Sunday, November 4, 8:45 - - 11 a.m. EST

"Phase 2 Trial of a 10-epitope CTL Vaccine, IDM-2101, in Metastatic NSCLC Patients: Induction of Immune Responses and Clinical Efficacy"

Dr. Minal Barve, practice director, Mary Crowley Medical Research Center

UVIDEM(R):

International Society for Biological Therapy of Cancer (iSBTc) -- Boston, Mass.

Poster presentation -- Friday, November 2, 10 a.m. -- 6 p.m. EDT

Saturday, November 3, 7 a.m. -- 6:30 p.m. EDT

"Clinical Efficacy and Immunogenicity of IDD-3/UVIDEM, a Dendritic Cell-based Vaccine, in Patients with Malignant Melanoma."

Poster #112

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

The presentations described in this press release will include forward- looking statements that reflect management's current views of future events regarding the development and characteristics of the Company's drug candidates L-MTP-PE, IDM-2101 and UVIDEM, including the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE and to respond to other matters raised by the FDA, the Company's confidence that the proposed NDA amendment will provide substantial evidence for the continued regulatory approval process, the review of the submissions for marketing approval of L-MTP-PE by the FDA and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products, and whether the cash resources of the Company will be sufficient to fund operations as planned, including any further clinical trials of any of the Company's product candidates. Additional risks with respect to L-MTP-PE in particular include, but are not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. These factors and others affecting the Company's business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended June 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
Breaking Medicine News(10 mins):